

# **CRISPR-Cas-based and Aptamer-based systems for diagnosing pathogens: a review**

**Helin Yu<sup>1,2</sup>, Wenwen Jing<sup>2</sup>, Xunjia, Cheng<sup>1,2,\*</sup>**

<sup>1</sup>Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China;

<sup>2</sup>Department of Medical Microbiology and parasitology, School of Basic Medical Science, Fudan University, Shanghai, China

Running head: A Review of Novel Pathogen Detection Tools

## **Abstract**

Pathogenic infections can cause severe clinical illnesses in humans and animals. Increased encounters between humans and animals and constant environmental changes exacerbate the transmission of zoonotic infectious diseases. Recently, World Health Organization has declared some zoonotic epidemics as public health emergencies of international concern. Hence, rapid and accurate detection of the causative pathogen is particularly essential in combating emerging and reemerging infectious diseases. Traditional pathogen detection tools are time-consuming, costly, and require skilled personnel, which greatly hinder the development of rapid diagnostic tests particularly in resource-constrained regions. Clustered regularly interspaced short palindromic repeats (CRISPR)-Cas- and aptamer-based platforms have replaced traditional pathogen detection methods. Here, we review two novel next-generation core pathogen detection platforms that are utilized for clinical and foodborne pathogenic microorganisms: CRISPR-Cas-based systems, including dCas9, Cas12a/b, Cas13, and Cas14 as well as, aptamer-based biosensor detection tools. We highlight CRISPR-Cas- and aptamer-based techniques and compare their strengths and

weaknesses. CRISPR-Cas-based tools require cumbersome procedures such as nucleic acid amplification and extraction, while aptamer-based tools require improved sensitivity. We review the combination of CRISPR-Cas- and aptamer-based techniques as a promising approach to overcome these deficiencies. Finally, we discuss Cas14-based tools as functionally stronger platforms for the detection of non-nucleic acid targets.

**Keywords:** clustered regularly interspaced short palindromic repeats-Cas; aptamer; pathogen detection; diagnostic tool

## **1. Introduction**

Zoonoses (infectious diseases transmitted between animals and humans) are widely prevalent worldwide, and viral infections are the most urgent emerging zoonoses [1-3]. Over 200 zoonoses that have been identified [4] include most of the emerging and reemerging infectious diseases [5]. Based on pathogenic characteristics, zoonoses can be classified as bacterial, viral, fungal, parasitic, rickettsial, and mycoplasma zoonoses [6]. For instance, plague [7], colibacillosis, and brucellosis [8] are zoonoses caused by bacteria; coronavirus disease (COVID-19) caused by severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2) [9], acquired immunodeficiency syndrome [10], Lassa fever [11], Ebola hemorrhagic fever [12], and Zika virus disease [13] are viral zoonoses; whereas cryptosporidiosis [14] and giardiasis [15] are zoonoses that arise from parasites. These diseases severely threaten human and animal health and can cause devastating global economic damage. Under the dual pressures of emerging and reemerging zoonoses, many uncertainties remain in the prevention and control of these infectious diseases. Furthermore, infections due to these pathogens do not respond well to treatment and are associated with low survival rates; thus, early disease diagnosis and pathogen identification are particularly important

in controlling the spread of zoonoses [3, 16, 17], with the current global SARS-CoV-2 pandemic a strong case in point.

The last two decades have witnessed a fast expansion in the repertoire of tools developed for pathogen detection. The clinical diagnosis of pathogens is generally based on the detection of pathogen-specific genes and proteins using techniques such as reverse transcription (RT)-polymerase chain reaction (PCR), RT-quantitative PCR (qPCR), enzyme-linked immunosorbent assay (ELISA), next-generation sequencing, fluorescence *in situ* hybridization (FISH), and chemiluminescence. These tools are very effective and have facilitated the evolution of diagnostics. However, traditional platforms including serological methods, which only workable after antibodies have been produced [18, 19], are time-consuming and can identify noncontagious cases as contagious (false-positive results), limiting the application of these methods in point-of-care testing (POCT). Pathogen detection tools based on antigen-antibody binding include ELISA [20], which is high in cost due to the heavy use of antibodies. Nucleic acid-based diagnostic methods, such as RT-PCR and RT-qPCR [21], are not convenient and require specialized equipment and trained personnel, although RT-qPCR is the gold-standard detection method for some RNA viruses such as SARS-CoV-2 [21, 22]. Nevertheless, nucleic acid-based tools have several advantages, including lower cost and higher sensitivity, over serological methods [23, 24]. Overall, these approaches are time-consuming, require strict operating procedures [25], are difficult in the rapid identification of pathogens, and cannot facilitate the interruption of pathogen transmission in real time, which is a challenge for global public health. In the setting of an increasing number of emerging and reemerging zoonotic pathogens circulating among human populations, such as SARS-CoV-2, which remains a pandemic since its emergence in late 2019,

there is an urgent need for the development of new diagnostic tools that should fulfill the affordable, sensitive, specific, user-friendly, rapid and robust, equipment-free, and deliverable to end-users [21].

Following the rapid evolution in our understanding of the clustered regularly interspaced short palindromic repeat (CRISPR)-Cas systems, different Cas effector proteins have been used for the identification of zoonotic pathogens based on their unique characteristics. This novel platform is highly dependent on nucleic acids isolated from pathogens and detection based on nucleic acid amplification. Isothermal amplification methods, such as recombinase polymerase amplification (RPA), loop-mediated isothermal amplification (LAMP), and RT-LAMP, are effective for pathogen detection in low-resource settings [19, 21, 26-28]. The CRISPR-Cas-based diagnostic platforms utilize isothermal amplification techniques to detect pathogens for high-speed POCT with improved sensitivity.

Aptamers, which are short single-stranded artificial oligo (deoxy) nucleotides, have several advantages over antibodies, including smaller molecular weight and easier synthesis and screening [29]. Many aptamer-based biosensor detection platforms that are combined with physical, chemical, and electrochemical approaches are widely used for POCT. These pathogen detection platforms often involve multiple disciplines. Although CRISPR-Cas- and aptamer-based detection methods provide several advantages over conventional tools for pathogen detection, deficiencies remain. For instance, CRISPR-Cas-based methods require nucleic acid extraction and amplification whereas aptamer-based detection methods require aptamer screening, which is time-consuming (Table 1). Recent studies have introduced the combination of CRISPR-Cas- and aptamer-based platforms as a way to overcome these shortcomings (Table 1). These novel

platforms exhibit robust detection capabilities and advantages over traditional methods and have potential utility for pathogen diagnosis and food health surveillance.

## **2. Rapid detection platforms based on CRISPR-Cas systems**

### **2.1 Discovery and evolution of the CRISPR-Cas systems**

CRISPRs are short palindromic DNA sequences discovered in the *Escherichia coli* genome in 1987 [30]; CRISPRs are absent in eukaryotes and viruses [31]. The two components of the CRISPR-Cas systems are Cas proteins, which are CRISPR-associated endonucleases that cleave specific sequences, and small guide RNAs (sgRNAs), which are composed of CRISPR RNA (crRNA) and trans-activating RNA and recognize substrate DNA or RNA and direct the Cas protein to the target site for editing. In nature, the CRISPR-Cas systems are part of the adaptive immune system of bacteria and archaea. Through the formation of RNA-guided endonuclease, CRISPR-Cas cleaves nucleic acids (DNA or RNA) that have invaded the prokaryote, thereby acting as a defense against foreign pathogens and plasmids [32-35]. The CRISPR-Cas systems involve three main phases of immunity: adaptation, expression/maturation, and interference [36-39]. Consequently, particular Cas proteins record nucleic acid information in the CRISPR array following the invasion of foreign mobile genetic elements. The effector complex formed by the endonuclease recognizes the exogenous nucleic acid information previously stored in the CRISPR array and cleaves the invading extraneous elements of secondary infection.

The CRISPR-Cas systems can be categorized into Class 1 and Class 2 based on genetic loci and the conserved sequences of the Cas protein. Class 1 CRISPR-Cas systems include types I, III, and IV, whereas Class 2 CRISPR-Cas systems include types II, V, and VI (Table 2) [40, 41]. Additionally, in contrast to Class 1 CRISPR-Cas systems, which are composed of multiple

proteins, Class 2 CRISPR-Cas systems, which are composed of a single protein, hold promise for utility in a wide range of applications in genome editing, gene regulation, molecular diagnostics, *in vitro* pathogen detection, and DNA imaging. Class 2 CRISPR-Cas systems, especially those including Cas9 and Cas12a (former known as Cpf1), have been more extensively studied than Class 1 CRISPR-Cas systems. The first Cas protein utilized in genetic manipulation is Cas9 purified from *Streptococcus pyogenes* (spCas9) [42]. However, activated Cas9 proteins, even those isolated from other bacteria, cannot be used for *in vitro* pathogen detection due to its lack of ability to nonspecifically cleave nucleic acids, whereas the subsequently identified Cas12a has been recognized to perform this function. Interestingly, deactivated Cas9 (dCas9) is primarily used for pathogen detection based on its sequence-specific binding feature in the absence of cleavage activity [43, 44]. Cas9 and Cas12a are the most extensively studied Cas proteins for gene editing and show promise for clinical applications [45]. With the advent of Cas12, Cas13, and Cas14, several rapid detection techniques based on CRISPR-Cas systems have been explored. Notably, both Cas12 and Cas14 belong to the type V CRISPR-Cas system; the latter occupies only half of the amino acids of the former and does not require the identification of the protospacer adjacent motif (PAM) sequence, which is necessary for recognition by Cas9 and Cas12 [46]. Consequently, Cas14 may have more robust features and applications than Cas12.

## **2.2 Gene editing and detection based on the type II CRISPR-Cas system**

CRISPR-Cas9 can cleave double-stranded DNA (dsDNA) [47], which can be inserted into exogenous gene fragments for homologous recombination or non-homologous end-joining repair for gene knock-in or knock-out purposes [37, 44, 48], and can be used to successfully edit diverse genes by changing the sequence of gRNA to arbitrarily switch genes of interest. In addition,

silence mutations in Cas9 that lead to dCas9 can be applied to diagnostics.

### ***CRISPR-dCas9***

The primary function of CRISPR-Cas9 is to splice target genes. Additionally, CRISPR-Cas9 can be applied to pathogen detection by exploiting its sequence-specific binding property that does not depend on cleavage activity (Figure 1). This detection procedure requires the introduction of two mutations to Cas9, which are D10A and H840A mutations in the RuvC-I and HNH nuclease domains, respectively [44, 48]. dCas9 harboring these silence mutations results in the removal of dsDNA cleavage activity, but exhibits strong affinity for it [49] and therefore can regulate the expression of endogenous genes without gene editing; this feature of dCas9 has been used for labeling specific sequences. The CRISPR-dCas9 system can be developed for genetic screening, overexpression of genes of interest, regulation of target gene expression using transcriptional activators and repressors, and gene detection [50]. The majority of CRISPR-dCas9-based diagnostic tools can detect different target pathogens by changing the sequence of sgRNA.

Assays based on CRISPR-dCas9 systems can potentially complement and enrich existing platforms used for pathogen detection. For instance, the CRISPR-Tag system can detect herpes simplex virus 1 DNA in host cells [51,52] and CRISPR-mediated DNA-FISH has been used as a convenient, high-speed detection approach for methicillin-resistant *Staphylococcus aureus* [53]. However, CRISPR-dCas9-based detection tools have not become mainstream diagnostic platforms.

### **2.3 Establishing rapid detection platforms based on CRISPR-Cas *trans*-cleavage activity**

Phylogenetic tree analysis has revealed that Cas12 and Cas14 belong to the Class 2, type V [54]. Unlike Cas9, Cas12a and Cas14 contain only one nuclease domain, RuvC (RuvC-I, RuvC-II, and RuvC-III), which cleaves DNA, whereas Cas13 contains two HNH domains, which cleave only

RNA [54-56]. Additionally, multiple Cas12 variants such as Cas12b, Cas12e, Cas12f, and Cas12j have been identified. Similar to Cas12a, Cas12b has been harnessed for the development of diagnostic tools [21]. Cas12e (formerly known as CasX) and Cas12j have been reported to edit the human genome [57-60]. A recent study demonstrated a novel method using for gene disruption and therapy using CRISPR-Cas12f, which was effectively packaged into an adeno-associated virus [45]. Given that dCas9, which has evolved from Cas9, can be used in diagnostics, whether these Cas12 variants can be applied to pathogen detection requires further investigation.

Notably, Cas12a, Cas12b, Cas13, and Cas14 possess collateral cleavage activity. The CRISPR-Cas systems can be activated to nonsepecifically cleave surrounding single-stranded DNA (ssDNA) or RNA following the recognition of predetermined specific sequences [54, 56, 61]. This collateral *trans*-cleavage activity is the basis for a highly sensitive and specific *in vitro* rapid detection platform that utilizes a single-stranded fluorescent reporter probe. The CasN-sgRNA complex, wherein CasN represents Cas12, Cas13, or Cas14, is combined with a target sequence that can activate the *trans*-cleavage activity of the Cas protein and to cut fluorescent probe, causing positive signals. Efficient degradation of the fluorescent probe can be used to confirm the presence of pathogens (Figure 1). CRISPR-Cas-based diagnostic tools convert the detection of target microorganism from a molecular level to a fluorescent signal that can be directly assessed by the naked eye or quickly identified by equipment, which is a more convenient, intuitive, and time-saving approach than conventional platforms.

In summary, the CRISPR-Cas systems have already been employed for the detection of disease-causing viruses, such as SARS-CoV-2 (Table 3), human papillomavirus (HPV) type 16 and type 18, human immunodeficiency virus (HIV), Zika virus (ZIKV), Dengue virus (DENV),



and for the testing of food for organisms such as *E. coli*, *S. aureus*, and *Salmonella enterica* serotype Enteritidis (*S. enteritidis*). Furthermore, the CRISPR-Cas systems have been harnessed to detect single-nucleotide polymorphisms (SNPs), genetic mutations, and cancer (Table 4).

### **2.3.1 Diagnostic tools based on type V CRISPR-Cas systems**

#### ***CRISPR-Cas12***

DNA endonuclease-targeted CRISPR trans reporter (DETECTR), which is based on Cas12a coupled with RPA, is a well-known diagnostic method that utilizes a fluorophore quencher (FQ)-labeled reporter gene to monitor the trans-cleavage activity of Cas12a [49, 61]. Typically, in the presence of pathogens, the DNA substrate binds to the Cas12a-gRNA complex to change the protein conformation of Cas12a. The nearby FQ-labeled ssDNA reporter is nonspecifically cleaved by Cas12a, resulting in the release of FQ and the recovery of the reporter fluorescence. Several Cas12-based diagnostic tools have been employed to detect various viruses, particularly SARS-CoV-2 following the global COVID-19 pandemic that emerged in late 2019 (Table 3). Notably, this system can quickly respond to emerging infectious pathogens and play a critical role in controlling epidemics and disease spread. Here, we overview a highly representative Cas12a-based tool developed for the detection of SARS-CoV-2.

SARS-CoV-2 can be detected by *in vitro* specific CRISPR-based assay for nucleic acid detection (iSCAN) [21], which combines a CRISPR-Cas12a detection system with the RT-LAMP technology. This novel detection platform, called two-pot iSCAN, has several benefits, including substantial time-saving, high accuracy, enforceability, and ease of operation [21, 41]. However, most CRISPR-Cas12a-based detection tools, including iSCAN platform, typically involve two steps, which complicate the testing process and increase the risk of contamination [86], POCT

may require minimal liquid handling and one-pot reactions. Normally, this barrier can be overcome by mixing all reaction components into a single tube for one-pot reaction [21, 87]. The one-pot iSCAN system can be used for robust testing and identification of other pathogens and provides a new basis for the development of early pathogen detection platforms. However, the application of one-pot detection systems to the domain of self-inspection by non-technical personnel faces substantial hurdles due to difficulties in finding suitable materials and carriers to control the incorporation of the Cas12a/b-sgRNA complex into the reaction system. A technique recently developed by Broughton *et al.* might be able to address this barrier [86].

The CRISPR-Cas12a diagnostic system relies on the indiscriminate cleavage of ssDNA by Cas12a activation. However, there are only two activation modes based on single- or double-stranded activators, which hinder specificity and universality [80]. Further, the Cas12a activation velocity affects the performance of the detection system. Therefore, new activation patterns have been developed to address these issues. A novel approach to detect *Pseudomonas aeruginosa*, developed by Sheng *et al.* [79], activates the CRISPR-Cas12a system by harnessing hydrazone chemistry, which has superior reactivity and selectivity [88, 89] and improves the specificity and flexibility of the method.

To break through the technical bottleneck created by the presence of only two activation methods, Khodakov *et al.* developed an unprecedented approach to Cas12 activation by employing toehold-mediated strand displacement reaction, which strictly follows base-pairing rules [90]. It can also be applied for the detection of DNA point mutations such as that is used in cancer diagnosis where DNA point mutations are a major cause of carcinogenesis and an important markers of prognostic and diagnosis [91-93]. Combination of specific techniques such

as RPA, LAMP, rolling circle amplification [94], and primer exchange reaction (PER) [95] with the CRISPR-Cas technology can promote the development of diagnostic platforms that use a one-step reaction as promising POCT tools [80, 96].

### ***CRISPR-Cas14***

Cas14, which was first reported in 2018 by Jennifer Doudna's group [54], has several unique traits compared to Cas12 [46]. Cas14a has 530 amino acids, which is the smallest RNA-guided nuclease identified to date; Cas14 can bind and cleave ssDNA, and RNA is a central component of the Cas14a-sgRNA complex [37, 46]. Cas14 also does not require a target sequence, such as PAM, for its cleavage activity [97, 98]. DETECTR-Cas14 is a recently developed diagnostic tool, which combines RPA tool with Cas14, and is based on the ability of Cas14 to cleave ssDNA through its nonspecific *trans*-cleavage activity [54]. This molecular scissors-based platform harnesses the ability of Cas14 to detect DNA with high fidelity to elicit the appearance of a fluorescent signal following the collateral cleavage of ssDNA [54]. This approach provides new possibilities for the detection of viruses [46,99]. However, the small number of studies that have reported CRISPR-Cas14-based diagnostic platforms only elucidate the prospects of their application. The DETECTR-Cas14 platform makes it possible to study the effects of ssDNA on the human virome, which is an important component in understanding the virus-disease associations [46, 100]. The CRISPR-Cas14-based platform still requires nucleic acid extraction and amplification, a procedure that is undoubtedly cumbersome. A new approach, heating unextracted diagnostic samples to obliterate nucleases (HUDSON), in combination with CRISPR-Cas14, without nucleic acids extraction process and shipping of the samples, simplified workflow [46, 82].

Furthermore, this new molecular scissors-based diagnostic tool exhibits great potential in SNP identification [54]. The CRISPR-Cas14 system has been applied to molecular diagnostics and SNP genotyping. In addition, CRISPR-Cas14 coupled with certain metal elements has also been harnessed for the sensitive detection of non-nucleic acid targets [101, 102]. There is no doubt that CRISPR-Cas14 can detect ssDNA viruses and foodborne bacteria in clinical settings; however, the CRISPR-Cas14-based diagnostic platforms have been explored to a more limited extent than the CRISPR-Cas12-based platforms. Therefore, their applicability for nondiagnostic purposes remains to be investigated.

### **2.3.2 Diagnostic tools built on type VI CRISPR-Cas systems**

#### ***CRISPR-Cas13***

CRISPR-Cas13-based platforms are promising diagnostic tools and potential next-generation diagnostic strategies for virus detection. Specific high-sensitivity enzymatic reporter unlocking (SHERLOCK) based on Cas13 was reported prior to the introduction of DETECTR; nonetheless, both approaches are based on similar detection principles and require combination with isothermal amplification technologies [82]. The CRISPR-Cas13-based diagnostic platforms can directly detect RNA viruses such as ZIKV, DENV, HIV, SARS, and SARS-CoV-2, because Cas13 identifies RNA substrates rather than DNA substrates. However, isothermal DNA amplification using RT-RPA can also detect DNA viruses [82]. Furthermore, SHERLOCK has been shown to detect pathogenic bacteria such as KPC and NDM-1. The next version of SHERLOCK, SHERLOCKv2, has been reported to provide a robust, 3.5-fold increase in sensitivity by coupling Cas13b to Csm6 [81].

Although SHERLOCK can specifically and precisely detect ZIKV and DENV at the level of 1 copy/ $\mu$ L [84], complicated operating procedures, especially nucleic acid extraction, have hindered its widespread utility. HUDSON was developed to compensate for this deficiency and to simplify SHERLOCK by reducing lysed viral particles and deactivating RNases in body fluids [82, 84]. It permits the use of RPA after HUDSON to directly detect virus from body fluids without the need for nucleic acid extraction, dilution, and purification [103]. A viral diagnostic platform by pairing SHERLOCK and HUDSON has been constructed to effectively and rapidly detect ZIKV and DENV [84]. This new platform is highly sensitive and specific and can be used without instruments. More importantly, it is a potential platform for multiplexing detection of viruses [81].

In 2020, Ackerman *et al.* [83] introduced combinatorial arrayed reactions for multiplexed evaluation of nucleic acids (CARMEN) as a flexible platform that enabled highly multiplexed detection of pathogens. The combination of CARMEN with Cas13 (CARMEN-Cas13) can stably detect more than 4500 crRNAs-substrate complexes in a single array. The CARMEN-Cas13 platform can detect Middle East respiratory syndrome virus, SARS, SARS-CoV-2, HIV, ZIKV, DENV, hepatitis C virus, and HPV4 but not  $\gamma$ HPV or arbo virus. The flexibility and high throughput of CARMEN allow the introduction of crRNAs or amplification primers to detect emerging and reemerging pathogens. Additionally, CARMEN complements the shortcomings of next-generation sequencing. In summary, the CARMEN-Cas13 platform expands the applications of CRISPR-based platforms for pathogen detection, by providing flexible testing.

### **3. Rapid detection platforms based on aptamers**

CRISPR-Cas-based diagnostic platforms are cumbersome due to complex manipulations that are needed such as extraction and amplification of nucleic acids. However, these tools have shown

robust functionality in pathogen detection and simple, convenient, and highly effective tools are urgently needed. Aptamer-based biosensor detection methods have subsequently attracted attention to address this issue.

Aptamers are 20–80-base ssDNA or RNA sequences identified by the screening of nucleic acid libraries with the systematic evolution of ligands by exponential enrichment (SELEX) strategy [104, 105]. Aptamers are excellent alternatives to antibodies for antigen-specific identification [106]. Furthermore, aptamers permit stable immobilization of target molecules such as viruses, bacteria, amino acids, proteins, and cells [107]. Typically, the screened aptamer binds specifically to the targeted substrate and indirectly detects pathogens based on physical, chemical, or electrochemical properties such as changes in current or electrical resistance or the naked-eye recognition of fluorescence. Therefore, platforms based on aptamer-based biosensors, i.e., aptasensors, have been broadly used to detect pathogenic viruses and foodborne bacteria in clinical settings or diagnosis of human diseases (Figure 1). Aptasensors are divided into optical and electronic biosensors depending on the type of transducer.

### **3.1 Detection of bacteria via aptamer-based tools**

Bacteria colonize a wide range of nature environments, and infection with pathogenic bacteria can cause severe clinical illness. Therefore, the early and rapid detection of bacteria in food or water samples is essential. Currently, most of the described aptamer-based detection tools are used for the detection of *E. coli* and *S. aureus*.

*E. coli* is a pathogenic microorganism widely found in nature and the human gut. Certain *E. coli* serotypes can cause various clinical symptoms, such as diarrhea, abdominal pain, ulcer, and hemolysis [108, 109]. *S. aureus* is a common pathogen that can cause various infectious diseases

such as pneumonia, arthritis, and sepsis [110]. In addition, following the abuse of antibiotics in clinical settings and their addition to poultry feed, *S. aureus* has gradually become insensitive to clinical treatment, a considerable challenge for human health [111]. Early and rapid diagnosis is very important in efforts to curb the spread of *E. coli* and *S. aureus*, guide medical treatment, and detect bacteria in food and water sources. Development of methods for the quantitative and rapid detection of *E. coli* and *S. aureus* has attracted the attention of food safety, medicine, and other fields, and fast and precise detection techniques based on aptamers have been exploited. The combination of optical or electrochemical sensors with aptamers has been widely used to test *E. coli* and *S. aureus* proteins and even whole cells.

### **3.1.1 Aptamers assembled with optical sensors for the detection of *E. coli* and *S. aureus***

Visible light, ultraviolet light, and fluorescent sensors can be used to detect *E. coli* using aptamers; these approaches provide several advantages including ease of operation and low cost compared to ELISA, which is a conventional technique that requires abundant amount of antibodies and is expensive [112]. Several optical-sensors-based tools for detecting *E. coli* have already been developed. In 2016, Fu *et al.* developed a method based on sandwich-like assay to detect *E. coli* K88 [113]. The authors introduced biotin-labeled and Au nanoparticle (NP)-labeled aptamers to create a sandwich-type complex (biotin-labeled aptamer I /*E. coli* K88/NP-labeled aptamer II). The presence of *E. coli* K88 was visualized based on a color reaction, and the assay had a linear range of  $10$ - $10^5$  colony-forming units (CFU)/mL. A colorimetric method based on an aptamer-polydiacetylene optical sensor was reported to detect *E. coli* O157:H7 at ranges between  $10^4$  and  $10^8$  CFU/mL [114]. Pandit *et al.* [115] developed a new method to detect *E. coli* in water samples. Specifically, two *E. coli*-specific aptamers, which were identified by screening, were separately

conjugated with superparamagnetic iron oxide NPs and CdTe-MPA quantum dots, respectively. The use of CdTe-MPA quantum dots allowed the qualitative and quantitative estimation of *E. coli* by fluorescence spectrophotometry. The limit of detection (LOD) of this biosensor was as high as 102 CFU. Yuan *et al.* [116] developed a gold NP-based colorimetric aptasensor to detect *S. aureus* based on tyramine signal amplification technology. In this method, the biotinylated anti- *S. aureus* aptamer is immobilized on the surface of a microtiter plate before the addition of other necessary ingredients (biotin-tyramine, streptavidin-horseradish peroxidase, avidin-catalase, *S. aureus*). The catalase added during the assay depletes endogenous hydrogen peroxide. Finally, gold (III) chloride trihydrate is used to change the color of the reaction product and the presence of *S. aureus* is determined by measuring absorbance at 550 nm. The assay could detect *S. aureus* ranging from  $10^{-10}$  CFU/mL under ideal conditions, and the LOD was 9 CFU/mL. Aptamer-based techniques using fluorescence for the detection of *E. coli* and *S. aureus* exhibit higher sensitivity than those based on visual and colorimetric assessment. However, fluorescence aptamer-based techniques often require sophisticated instruments such as epifluorescence, confocal fluorescence, and confocal laser scanning microscopy.

### **3.1.2 Aptamers assembled with electrochemical sensors for the detection of *E. coli* and *S. aureus***

Electrochemical signals can be displayed by current, resistance, or potential, offering several possibilities for constructing electrochemical biosensors for *E. coli* and *S. aureus* testing [112]. Notably, aptamers coupled to electrochemical sensor detection platforms have the potential to achieve tractability and miniaturization and have been reported to directly detect pathogens in turbid media. A study recently described a method to detect the outer membrane proteins (OMPs)



of *E. coli* through a change in resistance [117]. In that assay, potassium ferricyanide was used as a redox probe for electron exchange between the gold electrodes. *E. coli* OMPs combined with aptamers could hinder this process, leading to an electrochemical reaction. The relationship between the concentration of *E. coli* OMPs ( $1 \times 10^{-7}$ - $2 \times 10^{-6}$  mol/L) and electron-transfer resistance was excellent. In addition to OMPs, *E. coli* lipopolysaccharide can be used as a detection site [118]. Furthermore, aptamer-based electrochemical sensors can be used to detect *E. coli* genes. For instance, *E. coli* ribosomal RNA was detected by monitoring the oxidation state of guanine nucleotides [119], and *E. coli* genomic DNA was directly recognized by utilizing methylene blue as a DNA hybridization probe molecule [120]. Several tools have emerged for detecting whole cells of *E. coli* [121-123].

Nguyen *et al.* reported a new method for the detection of *S. aureus* [124]. The authors utilized a cognate pair of aptamers for *S. aureus* to fabricate a sandwich-type aptasensor (aptamer I /*S. aureus*/horseradish peroxidase-conjugated aptamer II ) on a screen-printed gold electrode. *S. aureus* can be detected based on a significant decrease in faradaic peak current and peak-to-peak potential separation. The predicted LOD of this sandwich-type signal-on electrochemical biosensor was 39 CFU in buffer and 414 CFU in commercially available bottled water samples. Further, it could easily detect *S. aureus* in a sample volume of as low as 5  $\mu$ L. As rapid, sample, sensitive, and specific approaches, sandwich-type electrochemical aptasensors have promising applicability in food safety management.

### **3.2 Detecting viruses via aptamer-based tools**

Aptamer-based biosensors have been developed for bacterial and viral detection. Table 5 summarizes the aptasensor-based techniques for the detection of viruses. Optical aptasensors for

virus detection can be categorized into six groups. Surface plasmon resonance (SPR) aptasensors are based on the detection of resonance of free electrons based on the change in refractive index. Aptamers are prefixed to the surface of a gold plate, and the thickness of the gold surface is altered after the capture of the virus; the presence of the virus is determined by measuring changes in the angle or the intensity of polarized light. Colorimetric aptasensors determine the presence of virus based on an apparent shift in color, which can be directly observed with the naked eye or using a spectrophotometer. Fluorescence aptasensors are based on the transition of fluorescence signals or the production of fluorescence polarization. Chemiluminescence (CL) aptasensors are commonly and extensively used to detect viruses, such as hepatitis B virus, HIV, SARS-CoV-2, and other emerging and reemerging infectious viruses in clinical practice. These assays are based on colorimetric detection. The aptamer is coincubated with virus particles, followed by the addition of catalytically active complexes, which bind to the virus, and the addition of a chromogenic or CL reagent for the quantitative detection of the virus. Surface-enhanced Raman scattering aptasensors utilize Raman scattering spectroscopy, which reflects the characteristics of the medium by the change in the energy of photons after passing a laser light through the medium. Interferometric aptasensors are the sixth category developed on the basis of interferometry. It is a label-free technique for measuring light intensity, which includes refractive index or physical property.

Furthermore, viruses can be detected with electronic biosensors, which are a type of electrochemical aptasensors, or piezoelectric transducers based on different mechanisms. Electrochemical aptasensors follow the principle of a change in electrical signal caused by the binding of the aptamer to the target virus. Aptamers used to capture viral molecules are prefixed

on electrode plates. Detection tools based on electrochemical aptasensors can be further categorized into three subclasses: enzymatically labeled aptasensors, where enzyme catalysis triggers a change in the electrical signals, enzyme-free aptasensors, where the binding of viral particles to the aptasensors directly causes a change in the electrical signal, and field-effect transistor (FET)-based aptasensors. In FET-based aptasensor detection tools, the aptamer is immobilized on the FET surface to capture target viral molecules and the change in the charge distribution on the FET surface is detected and translated into an easy-to-read signal. Several viral assays based on these technologies have been developed (Table 5). Piezoelectric transducers are based on the piezoelectric effect principle, in which an electrical charge is generated when certain materials are subjected to mechanical stress.

### **3.3 Detecting parasites via aptamer-based tools**

Parasites are a large family of pathogens that can cause zoonoses. Seven of the top 10 tropical diseases in the world are caused by parasites. As such, parasites are a serious threat to human health and a significant burden to the economy, both of which can be mitigated by the rapid detection of parasites. Recently developed aptamer-based tools for parasite detection provide rapid and accurate approaches with low LOD and have been widely implemented to identify and monitor various parasites.

Roca *et al.* selected a DNA aptamer (D10) against *Plasmodium falciparum* 1-deoxy-D-xylulose-5-phosphate reductoisomerase (DXR) using the SELEX strategy [159], a vital enzyme in the methyl erythritol phosphate (MEP) pathway of isoprenoid biosynthesis. D10 aptamer binds to recombinant DXR *in vitro* and explicitly targets the apicoplast, where the MEP pathway is localized, an essential organelle in *P. falciparum*. Therefore, D10 is a highly specific marker for

naive erythrocytes and red blood cells parasitized by *P. falciparum* and for the apicoplast. Consequently, D10 aptamer is a promising lead for future diagnostic strategies for *Plasmodium* and a potential tool for other studies of apicomplexan parasites such as *Toxoplasma gondii*. In addition, the D10 aptamer detects bacteria harboring the MEP pathway such as *E. coli* and *P. aeruginosa*. To address the lack of aptamer-based methods for the detection of SAG-1, the major *T. gondii* surface protein, Cui *et al.* [160] developed a direct enzyme-linked aptamer assay to target native SAG-1 (nSAG-1) for the detection of *T. gondii*. This novel technique is a potential tool for the rapid and precise diagnosis of toxoplasmosis. Homann *et al.* [161] is the first to employ the SELEX strategy to screen aptamers for the detection of African trypanosomes. The authors identified an RNA aptamer that crosslinked to a 42-kDa protein in the flagellar capsule of trypanosomes through 13 rounds of SELEX selection. Interestingly, although aptamer-based assays have been proposed for the detection of parasites, with many tools developed over years, only a handful of reports use whole cells as detection targets. Commonly, the screening substrates of aptamers for parasites are enzymes, proteins, and infected cells [162-164] and these aptamers detect the secretions and excretions of the target parasite or certain virulence-related molecules.

#### **4. Rapid detection platforms coupling CRISPR-Cas- and aptamer-based systems**

CRISPR-Cas- and aptamer-based techniques employ many tools for pathogen detection and exhibit robust efficacy, sensitivity, specificity, and convenience compared to conventional detection approaches; however, cumbersome procedures and the detection of the LOD are issues that remain to be resolved. For instance, CRISPR-Cas-based tools require nucleic acid extraction and amplification. Conversely, multiple rounds of aptamer screening are essential for aptamer-based platforms and detection with aptamers only does not achieve good sensitivity and the LOD

is usually in the picomolar and micromolar ranges [3, 165]. A study recently described that these two complementary techniques can be combined to develop effective detection tools for pathogen detection to address these obstacles (Figure 2). Notably, this cross-cutting approach has been used to detect pathogenic bacteria in samples, and should be studied more for the diagnosis of viruses or parasites, and therefore has promising applications in the POCT of foodborne bacteria. This CRISPR-Cas- and aptamer-based detection platform plays an essential role in preventing the spread of pathogens in resource-poor countries and regions. Meanwhile, some of the complementary tools can distinguish between dead and living bacteria, providing a feasible method for further control of pathogenic bacteria at the source.

#### **4.1 Diagnostic tools built on the CRISPR-Cas12 system coupled with aptamers**

Bu *et al.* constructed an electrochemical aptasensor to detect pathogenic bacteria without nucleic acid extraction by combining the CRISPR-Cas12a system with PER [166]. In this approach, the DNA aptamer binds to the hairpin loop of the primer, which remains inactivate in the absence of pathogens, thereby hindering primer amplification. In the presence of target bacteria, the DNA aptamer disentangles the hairpin loop structure and the primer is extended to form ssDNA, which activates the *trans*-cleavage activity of CRISPR-Cas12a to crush the MB probe pre-immobilized on the Au surface, resulting in a decrease in the monitored peak current. This novel technique has been utilized to detect bacteria in milk samples, such as the detection of *E. coli* O157:H7 with an LOD of 19 CFU/mL. To expand the repertoire of diagnostic methods for various disease biomarkers, Yuan *et al.* recently developed a “signal on-off-super on” sandwich-type aptasensor of CRISPR-Cas12a coupled voltage enrichment for the detection of vascular endothelial growth factor with an LOD of 0.33 pM [167]. In this technique, AuNPs@Ti3C2Tx-Mxene was

synthesized by immobilizing AuNPs on the surface of Ti<sub>3</sub>C<sub>2</sub>T<sub>x</sub>-Mxene, which stabilized the trapped the aptamer and therefore altered the electrochemical signal more effectively. This approach can enrich ssDNA using an electrochemical signal via CRISPR-Cas12a-coupled voltage enrichment instead of amplification.

#### **4.2 Diagnostic tools built on the CRISPR-Cas13 system coupled with aptamers**

Many platforms combining CRISPR-Cas13 with aptamers have been developed for pathogen detection. The difference between these platforms and the CRISPR-Cas12a-based platforms lies in the Cas enzyme. Shen *et al.* [168] presented the new APC-Cas platform for the detection of *S. enteritidis*. The allosteric probe used in this platform contains three sections: T7 promoter, aptamer, and primer-binding site. The probe is in a quiescent state due to the integration of the primer-binding site into the aptamer. In the presence of target pathogen, the allosteric probe undergoes conformational changes, and ssRNA is generated using the T7 RNA polymerase. The platform exhibited strong sensitivity and functionality for the quantitative detection of *S. enteritidis* and is promising approach for pathogen detection. Zhang *et al.* [169] reported a system to distinguish between viable and dead pathogenic bacteria using a light-up RNA aptamer combined with CRISPR-Cas13; the LOD of this system was 10 CFU for the detection of *Bacillus cereus*.

#### **4.3 Diagnostic tools built on the CRISPR-Cas14 system coupled with aptamers**

Cas14 is the smallest identified Cas enzyme and does not require PAM sequence identification; therefore, CRISPR-Cas14-based aptasensors exhibit enhanced sensitivity and versatility compared to the biosensors based on Cas12 or Cas13. Although reports of Cas14-based aptasensors are rare, they may be more potent. AcasB, a novel platform developed for on-site detection of live *S.*

*aureus*, contains an aptamer biosensor combined with Cas14a1 [3]. This platform includes three probes, a 45-nucleotide aptamer to target live *S. aureus*, a 21-nucleotide blocker for activation of Cas14a1, and an sgRNA to bind the blocker. Importantly, this platform does not require nucleic acid extraction and amplification. The blocker bound to the aptamer forms a stable hybrid, which dissociates to release the blocker in the presence of live *S. aureus* which specifically targets the aptamer. The subsequently released blocker activates Cas14a1 by binding to sgRNA, which then cleaves the surrounding fluorescence probe, resulting in fluorescence. This platform can directly distinguish whether the bacteria are alive or dead and has an LOD of 400 CFU/mL for live *S. aureus* in the tested samples.

Cas14 combined with aptamers can also be used to detect non-nucleic-acids targets. Zhou *et al.* developed a biosensor platform named highly sensitive aptamer-regulated Cas14 Rloop for bioanalysis (HARRY). In this platform, a diblock ssDNA is designed to accommodate the aptamer and Cas14 activation sequences. The ssDNA activates Cas14a, then the Cas14a *trans*-cleavages the fluorescent reporter, causing fluorescence enhancement in the absence of the target. Non-nucleic-acids substrates, such as ATP, Cd<sup>2+</sup>, histamine, aflatoxin B1, and thrombin, have been detected by the HARRY platform, which possesses LOD at the nanomolar level.

## 5. Conclusions and future perspectives

Pathogens pose a severe threat to the survival of humans and animals and are a public health issue of concern. CRISPR-Cas- and aptamer-based systems are harnessed for POCT research, primarily based on the application of CRISPR-Cas systems for pathogen detection. Conventional diagnostic methods are complicated and cumbersome. Therefore, diagnostic platforms based on the CRISPR-Cas system and aptamers have been exploited to improve detection efficiency and simplify the

procedures while reducing cost and improving applicability. Still, most of these tools are theoretical and few have been introduced for commercial use. The reasons that prevent their marketization, i.e., nucleic acid extraction and amplification, are a necessary component of CRISPR-Cas-based approaches, which are cumbersome processes that require skill. However, technological advances, such as isothermal amplification, microfluidics, and gene chips, should overcome these barriers [80]. SELEX is a time-consuming, not-yet-mature, costly, and unstable strategy, and sensitive simultaneous detection of multiple pathogens in a mixed medium is challenging. For clinical samples, the selected aptamers cannot be completely and accurately matched, and the affinity and specificity change [29]. Recent studies achieved the detection of pathogens in turbid media and the optimization of the SELEX screening process. Consequently, combination of the complementary CRISPR-Cas- and aptamer-based systems is an effective optimization approach to fill the gaps in pathogen detection. Indeed, the combination of these two systems has gradually replaced the traditional detection methods over the past decade. However, combinations of various Cas proteins with different aptamer techniques, such as allosteric probe-initiated catalysis and PER, are typically limited to bacterial detection, therefore, future studies should be conducted to advance viruses and parasites detection in clinical settings.

The recently described CRISPR FISHer [170] can potentially track particular cell-intrinsic or exogenous DNA sequences, broadening the application range of live cell imaging and laying the foundation for biomedical diagnostics. Several recent studies have identified new Cas proteins in nature. For instance, Cas12a2 [171, 172] is activated upon binding to RNA targets and can efficiently degrade ssRNA, ssDNA, and dsDNA. In contrast to the previously described Cas proteins, Cas12a2 is programmable and capable of pathogen detection. Cas14 is a newly discovered



and promising protein for the development of more efficient and convenient detection tools, while its use in conjunction with aptamer-based systems for the detection of non-nucleic acids offers a new idea for broadening diagnostic targets and establishing detection methods. However, many aspects of the mechanism of Cas proteins, both newly and previously discovered, are still not fully understood. In addition, combining several Cas proteins with different functions to enable simultaneous pathogen detection and treatment is an intriguing potential approach.

In conclusion, pathogen detection tools should be practical and generalizable, ideally with test results linked to a smartphone or smart bracelet, enabling citizens to self-testing for pathogens in food or water and alleviating stress. With the constant expansion of technology, there is great promise for improvement in diagnostics, and there is an urgent need to establish novel detection tools to respond rapidly to emerging zoonotic pathogens in the near future.

### **Acknowledgment**

This work was funded by Shanghai Municipal Science and Technology Major Project (ZD2021CY001). Figure 1&2 were created with BioRender.com.

### **Conflict of interest**

The authors declare no conflict of interest.

## References

1. Keesing F, Belden LK, Daszak P, Dobson A, Harvell CD, Holt RD, et al. Impacts of biodiversity on the emergence and transmission of infectious diseases. *Nature*. 2010;468(7324):647-52.
2. Mertz GJ. Zoonoses: infectious diseases transmissible from animals to humans, fourth edition. In: Wormser GP, editor: Oxford University Press; 2016. pp. 148-149.
3. Wei Y, Tao Z, Wan L, Zong C, Wu J, Tan X, et al. Aptamer-based Cas14a1 biosensor for amplification-free live pathogenic detection. *Biosens Bioelectron*. 2022;211:114282.
4. World Health Organization [<https://www.who.int/news-room/fact-sheets/detail/zoonoses>] Accessed on date 11/2022.
5. Jones KE, Patel NG, Levy MA, Storeygard A, Balk D, Gittleman JL, et al. Global trends in emerging infectious diseases. *Nature*. 2008;451(7181):990-993.
6. Chinese center for disease control and prevention. [<https://www.cdc.gov/onehealth/basics/zoonotic-diseases.html>. Available] Accessed on date 11/2022.
7. Jones SD, Atshabar B, Schmid BV, Zuk M, Amramina A, Stenseth NC. Living with plague: Lessons from the soviet Union's antiplague system. *Proc Natl Acad Sci U S a*. 2019;116(19):9155-9163.
8. Suarez-Esquivel M, Chaves-Olarte E, Moreno E, Guzman-Verri C. *Brucella* genomics: macro and micro evolution. *Int J Mol Sci*. 2020;21(20).

9. Van Kerkhove MD, Ryan MJ, Ghebreyesus TA. Preparing for "Disease X". *Science*. 2021;374(6566):377.
10. Sauter D, Kirchhoff F. Key viral adaptations preceding the AIDS pandemic. *Cell Host Microbe*. 2019;25(1):27-38.
11. Ogbu O, Ajuluchukwu E, Uneke CJ. Lassa fever in west African sub-region: an overview. *J Vector Borne Dis*. 2007;44(1):1-11.
12. Rewar S, Mirdha D. Transmission of Ebola virus disease: an overview. *Ann Glob Health*. 2014;80(6):444-51.
13. Hills SL, Morrison A, Stuck S, Sandhu K, Mason KL, Stanek D, et al. Case series of laboratory-associated Zika virus disease, United States, 2016-2019. *Emerg Infect Dis*. 2021;27(5):1296-1300.
14. Hotchkiss EJ. Zoonotic cryptosporidiosis-challenges for control and source attribution. *Vet Rec*. 2021;189(4):150-152.
15. Cai W, Ryan U, Xiao L, Feng Y. Zoonotic giardiasis: an update. *Parasitol Res*. 2021;120(12):4199-4218.
16. Bishara J, Leibovici L, Gartman-Israel D, Sagie A, Kazakov A, Miroshnik E, et al. Long-term outcome of infective endocarditis: the impact of early surgical intervention. *Clin Infect Dis*. 2001;33(10):1636-43.
17. van de Beek D, Brouwer M, Hasbun R, Koedel U, Whitney CG, Wijdicks E. Community-acquired bacterial meningitis. *Nat Rev Dis Primers*. 2016;2(1).
18. Dohla M, Boesecke C, Schulte B, Diegmann C, Sib E, Richter E, et al. Rapid point-of-care testing for SARS-CoV-2 in a community screening setting shows low sensitivity. *Public Health*.

2020;182(182):170-172.

19. Niemz A, Ferguson TM, Boyle DS. Point-of-care nucleic acid testing for infectious diseases.

Trends Biotechnol. 2011;29(5):240-50.

20. Ong D, Fragkou PC, Schweitzer VA, Chemaly RF, Moschopoulos CD, Skevaki C. How to interpret and use COVID-19 serology and immunology tests. Clin Microbiol Infect.

2021;27(7):981-986.

21. Ali Z, Aman R, Mahas A, Rao GS, Tehseen M, Marsic T, et al. iSCAN: An RT-LAMP-coupled CRISPR-Cas12 module for rapid, sensitive detection of SARS-CoV-2. Virus Res.

2020;288:198129.

22. Morshed MG, Lee MK, Jorgensen D, Isaac-Renton JL. Molecular methods used in clinical laboratory: prospects and pitfalls. FEMS Immunol Med Microbiol. 2007;49(2):184-91.

23. Qi X, Wang Z, Lu R, Liu J, Li Y, Chen Y. One-step and DNA amplification-free detection of *Listeria monocytogenes* in ham samples: Combining magnetic relaxation switching and DNA

hybridization reaction. Food Chem. 2021;338:127837.

24. Sheng L, Lu Y, Deng S, Liao X, Zhang K, Ding T, et al. A transcription aptasensor: amplified, label-free and culture-independent detection of foodborne pathogens via light-up RNA aptamers.

Chem Commun (Camb). 2019;55(68):10096-10099.

25. Zhang T, Zhou W, Lin X, Khan MR, Deng S, Zhou M, et al. Light-up RNA aptamer signaling-CRISPR-Cas13a-based mix-and-read assays for profiling viable pathogenic bacteria. Biosens

Bioelectron. 2021;176:112906.

26. Mori Y, Notomi T. Loop-mediated isothermal amplification (LAMP): a rapid, accurate, and cost-effective diagnostic method for infectious diseases. J Infect Chemother. 2009;15(2):62-9.

27. Notomi T, Okayama H, Masubuchi H, Yonekawa T, Watanabe K, Amino N, et al. Loop-mediated isothermal amplification of DNA. *Nucleic Acids Res.* 2000;28(12):E63.
28. Pang B, Xu J, Liu Y, Peng H, Feng W, Cao Y, et al. Isothermal amplification and ambient visualization in a single tube for the detection of SARS-CoV-2 using Loop-mediated amplification and CRISPR technology. *Anal Chem.* 2020;92(24):16204-16212.
29. Zou X, Wu J, Gu J, Shen L, Mao L. Application of aptamers in virus detection and antiviral therapy. *Front Microbiol.* 2019;10:1462.
30. Ishino Y, Shinagawa H, Makino K, Amemura M, Nakata A. Nucleotide sequence of the *iap* gene, responsible for alkaline phosphatase isozyme conversion in *Escherichia coli*, and identification of the gene product. *J Bacteriol.* 1987;169(12):5429-33.
31. Ding W, Zhang Y, Shi S. Development and Application of CRISPR/Cas in microbial biotechnology. *Front Bioeng Biotechnol.* 2020;8:711.
32. Chen JS, Ma E, Harrington LB, Da CM, Tian X, Palefsky JM, et al. Erratum for the report “ CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity ” . *Science.* 2021;371(6531).
33. East-Seletsky A, O'Connell MR, Knight SC, Burstein D, Cate JH, Tjian R, et al. Two distinct RNase activities of CRISPR-C2c2 enable guide-RNA processing and RNA detection. *Nature.* 2016;538(7624):270-273.
34. Makarova KS, Wolf YI, Alkhnbashi OS, Costa F, Shah SA, Saunders SJ, et al. An updated evolutionary classification of CRISPR-Cas systems. *Nat Rev Microbiol.* 2015;13(11):722-736.
35. Sorek R, Lawrence CM, Wiedenheft B. CRISPR-mediated adaptive immune systems in bacteria and archaea. *Annu Rev Biochem.* 2013;82:237-66.

36. Amitai G, Sorek R. CRISPR-Cas adaptation: insights into the mechanism of action. *Nat Rev Microbiol.* 2016;14(2):67-76.
37. Paul B, Montoya G. CRISPR-Cas12a: Functional overview and applications. *Biomed J.* 2020;43(1):8-17.
38. van der Oost J, Westra ER, Jackson RN, Wiedenheft B. Unravelling the structural and mechanistic basis of CRISPR-Cas systems. *Nat Rev Microbiol.* 2014;12(7):479-92.
39. Wright AV, Nuñez JK, Doudna JA. Biology and applications of CRISPR systems: harnessing nature's toolbox for genome engineering. *Cell.* 2016;164(1-2):29-44.
40. Nishimasu H, Nureki O. Structures and mechanisms of CRISPR RNA-guided effector nucleases Hiroshi Nishimasu<sup>1,2</sup> and Osamu Nureki<sup>1</sup>. *Curr Opin Struct Biol.* 2017;43:68-78.
41. Rahimi H, Salehiabar M, Barsbay M, Ghaffarlou M, Kavetsky T, Sharafi A, et al. CRISPR systems for COVID-19 diagnosis. *Acs Sens.* 2021;6(4):1430-1445.
42. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, et al. Multiplex genome engineering using CRISPR/Cas systems. *Science.* 2013;339(6121):819-23.
43. Doudna JA, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. *Science.* 2014;346(6213):1258096.
44. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. *Science.* 2012;337(6096):816-21.
45. Xin C, Yin J, Yuan S, Ou L, Liu M, Zhang W, et al. Comprehensive assessment of miniature CRISPR-Cas12f nucleases for gene disruption. *Nat Commun.* 2022;13(1).
46. Aquino-Jarquín G. CRISPR-Cas14 is now part of the artillery for gene editing and molecular diagnostic. *Nanomedicine (Lond).* 2019;18:428-431.

47. Chen JS, Ma E, Harrington LB, Da Costa M, Tian X, Palefsky JM, et al. Erratum for the Report "CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity". *Science*. 2021;371(6531).
48. Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin AP, et al. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. *Cell*. 2013;152(5):1173-83.
49. Kim S, Ji S, Koh HR. CRISPR as a Diagnostic Tool. *Biomolecules*. 2021;11(8):1162.
50. Moradpour M, Abdulah S. CRISPR/dCas9 platforms in plants: strategies and applications beyond genome editing. *Plant Biotechnol J*. 2020;18(1):32-44.
51. Xu H, Wang J, Deng Y, Hou F, Fu Y, Chen S, et al. Two-Color CRISPR Imaging Reveals Dynamics of Herpes Simplex Virus 1 Replication compartments and virus-host interactions. *J Virol*. 2022:e0092022.
52. Knipe DM, Cliffe A. Chromatin control of herpes simplex virus lytic and latent infection. *Nat Rev Microbiol*. 2008;6(3):211-221.
53. Guk K, Keem JO, Hwang SG, Kim H, Kang T, Lim E, et al. A facile, rapid and sensitive detection of MRSA using a CRISPR-mediated DNA FISH method, antibody-like dCas9/sgRNA complex. *Biosensors and Bioelectronics*. 2017;95:67-71.
54. Harrington LB, Burstein D, Chen JS, Paez-Espino D, Ma E, Witte IP, et al. Programmed DNA destruction by miniature CRISPR-Cas14 enzymes. *Science (American Association for the Advancement of Science)*. 2018;362(6416):839-842.
55. Qiu M, Zhou XM, Liu L. Improved strategies for CRISPR-Cas12-based nucleic acids detection. *J Anal Test*. 2022;6(1):44-52.

56. Shen J, Zhou X, Shan Y, Yue H, Huang R, Hu J, et al. Sensitive detection of a bacterial pathogen using allosteric probe-initiated catalysis and CRISPR-Cas13a amplification reaction. *Nat Commun.* 2020;11(1).
57. Burstein D, Harrington LB, Strutt SC, Probst AJ, Anantharaman K, Thomas BC, et al. New CRISPR-Cas systems from uncultivated microbes. *Nature.* 2017;542(7640):237-241.
58. Liu JJ, Orlova N, Oakes BL, Ma E, Spinner HB, Baney K, et al. CasX enzymes comprise a distinct family of RNA-guided genome editors. *Nature.* 2019;566(7743):218-223.
59. Tsuchida CA, Zhang S, Doost MS, Zhao Y, Wang J, O'Brien E, et al. Chimeric CRISPR-CasX enzymes and guide RNAs for improved genome editing activity. *Mol Cell.* 2022;82(6):1199-1209.e6.
60. Wang Y, Qi T, Liu J, Yang Y, Wang Z, Wang Y, et al. A highly specific CRISPR-Cas12j nuclease enables allele-specific genome editing. *Sci Adv.* 2023;9(6):eabo6405.
61. Chen JS, Ma E, Harrington LB, Da Costa M, Tian X, Palefsky JM, et al. CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity. *Science (American Association for the Advancement of Science).* 2018;360(6387):436-439.
62. Broughton JP, Deng X, Yu G, Fasching CL, Servellita V, Singh J, et al. CRISPR-Cas12-based detection of SARS-CoV-2. *Nat Biotechnol.* 2020;38(7):870-874.
63. Wang X, Zhong M, Liu Y, Ma P, Dang L, Meng Q, et al. Rapid and sensitive detection of COVID-19 using CRISPR/Cas12a-based detection with naked eye readout, CRISPR/Cas12a-NER. *Sci Bull (Beijing).* 2020;65(17):1436-1439.
64. Ding X, Yin K, Li Z, Liu C. All-in-One Dual CRISPR-Cas12a (AIOD-CRISPR) Assay: a case for rapid, ultrasensitive and visual detection of novel coronavirus SARS-CoV-2 and HIV virus.



bioRxiv. 2020.

65. Joung J, Ladha A, Saito M, Kim NG, Woolley AE, Segel M, et al. Detection of SARS-CoV-2 with SHERLOCK one-pot testing. *N Engl J Med*. 2020;383(15):1492-1494.

66. Sun Y, Yu L, Liu C, Ye S, Chen W, Li D, et al. One-tube SARS-CoV-2 detection platform based on RT-RPA and CRISPR/Cas12a. *J Transl Med*. 2021;19(1):74.

67. Jiang Y, Hu M, Liu AA, Lin Y, Liu L, Yu B, et al. Detection of SARS-CoV-2 by CRISPR/Cas12a-Enhanced colorimetry. *Acs Sens*. 2021;6(3):1086-1093.

68. Lu S, Tong X, Han Y, Zhang K, Zhang Y, Chen Q, et al. Fast and sensitive detection of SARS-CoV-2 RNA using suboptimal protospacer adjacent motifs for Cas12a. *Nat Biomed Eng*. 2022;6(3):286-297.

69. Guo L, Sun X, Wang X, Liang C, Jiang H, Gao Q, et al. SARS-CoV-2 detection with CRISPR diagnostics. *Cell Discov*. 2020; 6:34.

70. Hou T, Zeng W, Yang M, Chen W, Ren L, Ai J, et al. Development and evaluation of a rapid CRISPR-based diagnostic for COVID-19. *Plos Pathog*. 2020;16(8): e1008705.

71. Rauch JN, Valois E, Solley SC, Braig F, Lach RS, Audouard M, et al. A scalable, easy-to-deploy protocol for Cas13-Based detection of SARS-CoV-2 genetic material. *J Clin Microbiol*. 2021;59(4).

72. Chen JS, Ma E, Harrington LB, Da CM, Tian X, Palefsky JM, et al. CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity. *Science*. 2018;360(6387):436-439.

73. Zhang D, Yan Y, Que H, Yang T, Cheng X, Ding S, et al. CRISPR/Cas12a-mediated interfacial cleaving of hairpin DNA reporter for electrochemical nucleic acid sensing. *Acs Sens*.

2020;5(2):557-562.

74. He Q, Yu D, Bao M, Korensky G, Chen J, Shin M, et al. High-throughput and all-solution phase African Swine Fever Virus (ASFV) detection using CRISPR-Cas12a and fluorescence based point-of-care system. *Biosens Bioelectron.* 2020; 154:112068.

75. Lu S, Li F, Chen Q, Wu J, Duan J, Lei X, et al. Rapid detection of African swine fever virus using Cas12a-based portable paper diagnostics. *Cell Discov.* 2020;6:18.

76. Li SY, Cheng QX, Wang JM, Li XY, Zhang ZL, Gao S, et al. CRISPR-Cas12a-assisted nucleic acid detection. *Cell Discov.* 2018;4:20.

77. Li L, Li S, Wu N, Wu J, Wang G, Zhao G, et al. HOLMESv2: A CRISPR-Cas12b-assisted platform for nucleic acid detection and DNA methylation quantitation. *Acs Synth Biol.* 2019;8(10):2228-2237.

78. English MA, Soenksen LR, Gayet RV, de Puig H, Angenent-Mari NM, Mao AS, et al. Programmable CRISPR-responsive smart materials. *Science.* 2019;365(6455):780-785.

79. Sheng AZ, Yang JY, Tang LF, Niu LL, Cheng LF, Zeng YJ, et al. Hydrazone chemistry-mediated CRISPR/Cas12a system for bacterial analysis. *Nucleic Acids Res.* 2022;50(18):10562-10570.

80. Wu Y, Luo W, Weng Z, Guo Y, Yu H, Zhao R, et al. A PAM-free CRISPR/Cas12a ultra-specific activation mode based on toehold-mediated strand displacement and branch migration. *Nucleic Acids Res.* 2022;50(20):11727-11737.

81. Gootenberg JS, Abudayyeh OO, Kellner MJ, Joung J, Collins JJ, Zhang F. Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6. *Science.* 2018;360(6387):439-444.

82. Gootenberg JS, Abudayyeh OO, Lee JW, Essletzbichler P, Dy AJ, Joung J, et al. Nucleic acid detection with CRISPR-Cas13a/C2c2. *Science*. 2017;356(6336):438-442.
83. Ackerman CM, Myhrvold C, Thakku SG, Freije CA, Metsky HC, Yang DK, et al. Massively multiplexed nucleic acid detection with Cas13. *Nature*. 2020;582(7811):277-282.
84. Myhrvold C, Freije CA, Gootenberg JS, Abudayyeh OO, Metsky HC, Durbin AF, et al. Field-deployable viral diagnostics using CRISPR-Cas13. *Science*. 2018;360(6387):444-448.
85. Chen W, Luo H, Zeng L, Pan Y, Parr JB, Jiang Y, et al. A suite of PCR-LwCas13a assays for detection and genotyping of *Treponema pallidum* in clinical samples. *Nat Commun*. 2022;13(1):4671.
86. Chen Y, Xu X, Wang J, Zhang Y, Zeng W, Liu Y, et al. Photoactivatable CRISPR/Cas12a Strategy for One-Pot DETECTR Molecular Diagnosis. *Anal Chem*. 2022;94(27):9724-9731.
87. Aman R, Marsic T, Sivakrishna RG, Mahas A, Ali Z, Alsanea M, et al. iSCAN-V2: A One-pot RT-RPA-CRISPR/Cas12b assay for point-of-care SARS-CoV-2 detection. *Front Bioeng Biotechnol*. 2021;9:800104.
88. Chen T, Sheng A, Hu Y, Mao D, Ning L, Zhang J. Modularization of three-dimensional gold nanoparticles/ferrocene/liposome cluster for electrochemical biosensor. *Biosens Bioelectron*. 2019;124-125:115-121.
89. Hang HC, Bertozzi CR. Chemoselective approaches to glycoprotein assembly. *Acc Chem Res*. 2001;34(9):727-36.
90. Khodakov DA, Khodakova AS, Linacre A, Ellis AV. Toehold-mediated nonenzymatic DNA strand displacement as a platform for DNA genotyping. *J Am Chem Soc*. 2013;135(15):5612-9.
91. Bronner CE, Baker SM, Morrison PT, Warren G, Smith LG, Lescoe MK, et al. Mutation in the

DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. *Nature*. 1994;368(6468):258-61.

92. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. *Cancer Res*. 2006;66(8):3992-5.

93. Shah SP, Morin RD, Khattra J, Prentice L, Pugh T, Burleigh A, et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. *Nature*. 2009;461(7265):809-813.

94. Tian B, Minero G, Fock J, Dufva M, Hansen MF. CRISPR-Cas12a based internal negative control for nonspecific products of exponential rolling circle amplification. *Nucleic Acids Res*. 2020;48(5):e30.

95. Dai Y, Xu W, Somoza RA, Welter JF, Caplan AI, Liu CC. An integrated multi-function heterogeneous biochemical circuit for high-resolution electrochemistry-based genetic analysis. *Angew Chem Int Ed Engl*. 2020;59(46):20545-20551.

96. Ding X, Yin K, Li Z, Lalla RV, Ballesteros E, Sfeir MM, et al. Ultrasensitive and visual detection of SARS-CoV-2 using all-in-one dual CRISPR-Cas12a assay. *Nat Commun*. 2020;11(1):4711.

97. Hillary VE, Ceasar SA. A review on the mechanism and applications of CRISPR/Cas9/Cas12/Cas13/Cas14 proteins utilized for genome engineering. *Mol Biotechnol*. 2022.

98. Zetsche B, Gootenberg JS, Abudayyeh OO, Slaymaker IM, Makarova KS, Essletzbichler P, et al. Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. *Cell*. 2015;163(3):759-71.

99. Guido M, Tumolo MR, Verri T, Romano A, Serio F, De Giorgi M, et al. Human bocavirus:

- Current knowledge and future challenges. *World J Gastroenterol*. 2016;22(39):8684-8697.
100. Krupovic M, Forterre P. Single-stranded DNA viruses employ a variety of mechanisms for integration into host genomes. *Ann N Y Acad Sci*. 2015;1341:41-53.
101. Hu J, Zhou J, Liu R, Lv Y. Element probe based CRISPR/Cas14 bioassay for non-nucleic-acid targets. *Chemical communications (Cambridge, England)*. 2021;57(8):1423-1426.
102. Wu P, Ye X, Wang D, Gong F, Wei X, Xiang S, et al. A novel CRISPR/Cas14a system integrated with 2D porphyrin metal-organic framework for microcystin-LR determination through a homogeneous competitive reaction. *J Hazard Mater*. 2022;424(Pt D):127690-127690.
103. Arizti-Sanz J, Freije CA, Stanton AC, Petros BA, Boehm CK, Siddiqui S, et al. Streamlined inactivation, amplification, and Cas13-based detection of SARS-CoV-2. *Nat Commun*. 2020;11(1):5921.
104. Kanwar JR, Mohan RR, Kanwar RK, Roy K, Bawa R. Applications of aptamers in nanodelivery systems in cancer, eye and inflammatory diseases. *Nanomedicine (Lond)*. 2010;5(9):1435-45.
105. Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. *Science*. 1990;249(4968):505-10.
106. Thiviyanathan V, Gorenstein DG. Aptamers and the next generation of diagnostic reagents. *Proteomics Clin Appl*. 2012;6(11-12):563-73.
107. Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. *Nature*. 1990;346(6287):818-22.
108. Manning SD, Motiwala AS, Springman AC, Qi W, Lacher DW, Ouellette LM, et al. Variation in virulence among clades of *Escherichia coli* O157:H7 associated with disease

outbreaks. Proc Natl Acad Sci U S a. 2008;105(12):4868-73.

109. Saxena T, Kaushik P, Krishna MM. Prevalence of *E. coli* O157:H7 in water sources: an overview on associated diseases, outbreaks and detection methods. Diagn Microbiol Infect Dis. 2015;82(3):249-64.

110. Chakraborty SP, Mahapatra SK, Sahu SK, Chattopadhyay S, Pramanik P, Roy S. Nitric oxide mediated staphylococcus aureus pathogenesis and protective role of nanoconjugated vancomycin. Asian Pac J Trop Biomed. 2011;1(2):102-9.

111. Hiramatsu K, Katayama Y, Matsuo M, Sasaki T, Morimoto Y, Sekiguchi A, et al. Multi-drug-resistant staphylococcus aureus and future chemotherapy. J Infect Chemother. 2014;20(10):593-601.

112. Zhao YW, Wang HX, Jia GC, Li Z. Application of aptamer-based biosensor for rapid detection of pathogenic *Escherichia coli*. Sensors (Basel). 2018;18(8).

113. Meng-Yu FU, Li-Ping L, Yun WU, Jin W, Guo-Ping WU. Establishment of a visual and rapid detection method for enterotoxigenic *Escherichia coli* K88. Modern Food Science & Technology. 2016;32(10):283-289.

114. Wu W, Zhang J, Zheng M, Zhong Y, Yang J, Zhao Y, et al. An aptamer-based biosensor for colorimetric detection of *Escherichia coli* O157:H7. Plos One. 2012;7(11):e48999.

115. Pandit C, Alajangi HK, Singh J, Khajuria A, Sharma A, Hassan MS, et al. Development of magnetic nanoparticle assisted aptamer-quantum dot based biosensor for the detection of *Escherichia coli* in water samples. Sci Total Environ. 2022;831:154857.

116. Yuan J, Wu S, Duan N, Ma X, Xia Y, Chen J, et al. A sensitive gold nanoparticle-based colorimetric aptasensor for *Staphylococcus aureus*. Talanta. 2014;127:163-8.

117. Queirós RB, De-Los-Santos-álvarez N, Noronha JP, Sales MGF. A label-free DNA aptamer-based impedance biosensor for the detection of *E. coli* outer membrane proteins. *Sensors and Actuators B: Chemical*. 2013;181:766-772.
118. Jiang Y, Zou S, Cao X. A simple dendrimer-aptamer based microfluidic platform for *E. coli* O157:H7 detection and signal intensification by rolling circle amplification. *Sensors and Actuators B: Chemical*. 2017;251:976-984.
119. Lagier MJ, Scholin CA, Fell JW, Wang J, Goodwin KD. An electrochemical RNA hybridization assay for detection of the fecal indicator bacterium *Escherichia coli*. *Mar Pollut Bull*. 2005;50(11):1251-61.
120. Arora K, Prabhakar N, Chand S, Malhotra BD. *Escherichia coli* genosensor based on polyaniline. *Anal Chem*. 2007;79(16):6152-8.
121. Brosel-Oliu S, Ferreira R, Uria N, Abramova N, Gargallo R, Muñoz-Pascual F, et al. Novel impedimetric aptasensor for label-free detection of *Escherichia coli* O157:H7. *Sensors and Actuators B: Chemical*. 2018;255:2988-2995.
122. Ding S, Mosher C, Lee XY, Das SR, Cargill AA, Tang X, et al. Rapid and label-free detection of interferon *Gamma* via an electrochemical aptasensor comprising a ternary surface monolayer on a gold interdigitated electrode array. *Acs Sens*. 2017;2(2):210-217.
123. Hao N, Zhang X, Zhou Z, Hua R, Zhang Y, Liu Q, et al. AgBr nanoparticles/3D nitrogen-doped graphene hydrogel for fabricating all-solid-state luminol-electrochemiluminescence *Escherichia coli* aptasensors. *Biosens Bioelectron*. 2017;97:377-383.
124. Nguyen TT, Kim ER, Gu MB. A new cognate aptamer pair-based sandwich-type electrochemical biosensor for sensitive detection of *Staphylococcus aureus*. *Biosens Bioelectron*.

2022;198:113835.

125. Bai H, Wang R, Hargis B, Lu H, Li Y. A SPR aptasensor for detection of avian influenza virus H5N1. *Sensors (Basel)*. 2012;12(9):12506-18.

126. Nguyen VT, Seo HB, Kim BC, Kim SK, Song CS, Gu MB. Highly sensitive sandwich-type SPR based detection of whole H5Nx viruses using a pair of aptamers. *Biosens Bioelectron*. 2016;86:293-300.

127. Tombelli S, Minunni M, Luzzi E, Mascini M. Aptamer-based biosensors for the detection of HIV-1 tat protein. *Bioelectrochemistry*. 2005;67(2):135-41.

128. Weerathunge P, Ramanathan R, Torok VA, Hodgson K, Xu Y, Goodacre R, et al. Ultrasensitive colorimetric detection of murine norovirus using nanozyme aptasensor. *Anal Chem*. 2019;91(5):3270-3276.

129. Chen C, Zou Z, Chen L, Ji X, He Z. Functionalized magnetic microparticle-based colorimetric platform for influenza A virus detection. *Nanotechnology*. 2016;27(43):435102.

130. Shiratori I, Akitomi J, Boltz DA, Horii K, Furuichi M, Waga I. Selection of DNA aptamers that bind to influenza A viruses with high affinity and broad subtype specificity. *Biochem Biophys Res Commun*. 2014;443(1):37-41.

131. Kim SH, Lee J, Lee BH, Song CS, Gu MB. Specific detection of avian influenza H5N2 whole virus particles on lateral flow strips using a pair of sandwich-type aptamers. *Biosens Bioelectron*. 2019;134:123-129.

132. Liu M, Zhao H, Chen S, Yu H, Quan X. Interface engineering catalytic graphene for smart colorimetric biosensing. *Acs Nano*. 2012;6(4):3142-51.

133. Park JH, Jee MH, Kwon OS, Keum SJ, Jang SK. Infectivity of hepatitis C virus correlates



with the amount of envelope protein E2: development of a new aptamer-based assay system suitable for measuring the infectious titer of HCV. *Virology*. 2013;439(1):13-22.

134. Escudero-Abarca BI, Suh SH, Moore MD, Dwivedi HP, Jaykus LA. Selection, characterization and application of nucleic acid aptamers for the capture and detection of human norovirus strains. *Plos One*. 2014;9(9):e106805.

135. Lee KH, Zeng H. Aptamer-Based ELISA Assay for Highly Specific and Sensitive Detection of Zika NS1 Protein. *Anal Chem*. 2017;89(23):12743-12748.

136. Le TT, Chang P, Benton DJ, Mccauley JW, Iqbal M, Cass A. Dual recognition element lateral flow assay toward multiplex strain specific influenza virus detection. *Anal Chem*. 2017;89(12):6781-6786.

137. Yeom G, Kang J, Jang H, Nam HY, Kim MG, Park CJ. Development of DNA aptamers against the nucleocapsid protein of severe fever with Thrombocytopenia Syndrome Virus for diagnostic application: catalytic signal amplification using replication protein A-conjugated liposomes. *Anal Chem*. 2019;91(21):13772-13779.

138. Chen Z, Wu Q, Chen J, Ni X, Dai J. A DNA aptamer based method for detection of SARS-CoV-2 nucleocapsid protein. *Virol Sin*. 2020;35(3):351-354.

139. Zhang L, Fang X, Liu X, Ou H, Zhang H, Wang J, et al. Discovery of sandwich type COVID-19 nucleocapsid protein DNA aptamers. *Chem Commun (Camb)*. 2020;56(70):10235-10238.

140. Suh SK, Song S, Oh HB, Hwang SH, Hah SS. Aptamer-based competitive binding assay for one-step quantitation of hepatitis B surface antigen. *Analyst*. 2014;139(17):4310-4.

141. Pramanik A, Gao Y, Patibandla S, Mitra D, Mccandless MG, Fassero LA, et al. Aptamer

conjugated gold nanostar-based distance-dependent nanoparticle surface energy transfer spectroscopy for ultrasensitive detection and inactivation of corona virus. *J Phys Chem Lett.* 2021;12(8):2166-2171.

142. Szakacs Z, Meszaros T, de Jonge MI, Gyurcsanyi RE. Selective counting and sizing of single virus particles using fluorescent aptamer-based nanoparticle tracking analysis. *Nanoscale.* 2018;10(29):13942-13948.

143. Zhang J, Tian J, He Y, Chen S, Jiang Y, Zhao Y, et al. Protein-binding aptamer assisted signal amplification for the detection of influenza A (H1N1) DNA sequences based on quantum dot fluorescence polarization analysis. *Analyst.* 2013;138(17):4722-7.

144. Ahn DG, Jeon IJ, Kim JD, Song MS, Han SR, Lee SW, et al. RNA aptamer-based sensitive detection of SARS coronavirus nucleocapsid protein. *Analyst.* 2009;134(9):1896-901.

145. Xi Z, Huang R, Li Z, He N, Wang T, Su E, et al. Selection of HBsAg-specific DNA aptamers based on carboxylated magnetic nanoparticles and their application in the rapid and simple detection of Hepatitis B virus infection. *Acs Appl Mater Interfaces.* 2015;7(21):11215-23.

146. Liu J, Qin Q, Zhang X, Li C, Yu Y, Huang X, et al. Development of a novel lateral flow biosensor combined with aptamer-based isolation: application for rapid detection of grouper nervous necrosis virus. *Front Microbiol.* 2020;11:886.

147. Roh C, Kim SE, Jo SK. Label free inhibitor screening of hepatitis C virus (HCV) NS5B viral protein using RNA oligonucleotide. *Sensors (Basel).* 2011;11(7):6685-96.

148. Park JA, Kim J, Kim SM, Sohn H, Park C, Kim TH, et al. Fabrication of electrochemical influenza virus (H1N1) biosensor composed of multifunctional DNA four-way junction and molybdenum disulfide hybrid material. *Materials (Basel).* 2021;14(2).

149. Rahmati Z, Roushani M, Hosseini H. Three-dimensional NiCo<sub>2</sub>O<sub>4</sub> nanowires encapsulated in nitrogen-doped carbon networks as a high-performance aptamer stabilizer for impedimetric ultrasensitive detection of hepatitis C virus core antigen. *Surf Interfaces*. 2021;22:100813.
150. Ghanbari K, Roushani M, Azadbakht A. Ultra-sensitive aptasensor based on a GQD nanocomposite for detection of hepatitis C virus core antigen. *Anal Biochem*. 2017;534:64-69.
151. Fu Y, Callaway Z, Lum J, Wang R, Lin J, Li Y. Exploiting enzyme catalysis in ultra-low ion strength media for impedance biosensing of avian influenza virus using a bare interdigitated electrode. *Anal Chem*. 2014;86(4):1965-71.
152. Wang R, Xu L, Li Y. Bio-nanogate controlled enzymatic reaction for virus sensing. *Biosens Bioelectron*. 2015;67:400-7.
153. Rahim RA, Tanabe K, Ibori S, Wang X, Kawarada H. Effects of diamond-FET-based RNA aptamer sensing for detection of real sample of HIV-1 tat protein. *Biosens Bioelectron*. 2013;40(1):277-82.
154. Seo G, Lee G, Kim MJ, Baek SH, Choi M, Ku KB, et al. Rapid detection of COVID-19 causative virus (SARS-CoV-2) in human nasopharyngeal swab specimens using field-effect transistor-based biosensor. *Acs Nano*. 2020;14(4):5135-5142.
155. Giamberardino A, Labib M, Hassan EM, Tetro JA, Springthorpe S, Sattar SA, et al. Ultrasensitive norovirus detection using DNA aptasensor technology. *Plos One*. 2013;8(11):e79087.
156. Minunni M, Tombelli S, Gullotto A, Luzi E, Mascini M. Development of biosensors with aptamers as bio-recognition element: the case of HIV-1 tat protein. *Biosens Bioelectron*. 2004;20(6):1149-56.

157. Wang R, Li Y. Hydrogel based QCM aptasensor for detection of avian influenza virus. *Biosens Bioelectron.* 2013;42:148-55.
158. Pleshakova TO, Kaysheva AL, Bayzyanova Jcapital Em C, Anashkina Capital A C, Uchaikin VF, Ziborov VS, et al. The detection of hepatitis c virus core antigen using afm chips with immobilized aptamers. *J Virol Methods.* 2018;251:99-105.
159. Roca C, Avalos-Padilla Y, Prieto-Simon B, Iglesias V, Ramirez M, Imperial S, et al. Selection of an aptamer against the enzyme 1-deoxy-D-xylulose-5-phosphate reductoisomerase from *Plasmodium falciparum*. *Pharmaceutics.* 2022;14(11).
160. Cui W, Shen X, Wang C, Bibi A, Cudjoe O, Zhao L, et al. Direct enzyme-linked aptamer assay (DELAA) for diagnosis of *Toxoplasmosis* by detection of SAG1 protein in mice and humans. *Acta Trop.* 2022;226:106255.
161. Homann M, Goringe HU. Combinatorial selection of high affinity RNA ligands to live African trypanosomes. *Nucleic Acids Res.* 1999;27(9):2006-14.
162. Cheung YW, Kwok J, Law AW, Watt RM, Kotaka M, Tanner JA. Structural basis for discriminatory recognition of *Plasmodium* lactate dehydrogenase by a DNA aptamer. *Proc Natl Acad Sci U S a.* 2013;110(40):15967-72.
163. Joseph DF, Nakamoto JA, Garcia RO, Penaranda K, Sanchez-Castro AE, Castillo PS, et al. DNA aptamers for the recognition of HMGB1 from *Plasmodium falciparum*. *Plos One.* 2019;14(4):e0211756.
164. Oteng EK, Gu W, McKeague M. High-efficiency enrichment enables identification of aptamers to circulating *Plasmodium falciparum*-infected erythrocytes. *Sci Rep.* 2020;10(1):9706.
165. Acquah C, Agyei D, Obeng EM, Pan S, Tan KX, Danquah MK. Aptamers: an emerging class

of bioaffinity ligands in bioactive peptide applications. *Crit Rev Food Sci Nutr*. 2020;60(7):1195-1206.

166. Bu S, Liu X, Wang Z, Wei H, Yu S, Li Z, et al. Ultrasensitive detection of pathogenic bacteria by CRISPR/Cas12a coupling with a primer exchange reaction. *Sensors and Actuators B: Chemical*. 2021;347:130630.

167. Yuan G, Xia X, Zhang J, Huang J, Xie F, Li X, et al. A novel “signal on-off-super on” sandwich-type aptamer sensor of CRISPR-Cas12a coupled voltage enrichment assay for VEGF detection. *Biosensors and Bioelectronics*. 2023;221:114424.

168. Shen J, Zhou X, Shan Y, Yue H, Huang R, Hu J, et al. Sensitive detection of a bacterial pathogen using allosteric probe-initiated catalysis and CRISPR-Cas13a amplification reaction. *Nat Commun*. 2020;11(1):267.

169. Zhang T, Zhou W, Lin X, Khan MR, Deng S, Zhou M, et al. Light-up RNA aptamer signaling-CRISPR-Cas13a-based mix-and-read assays for profiling viable pathogenic bacteria. *Biosens Bioelectron*. 2021;176:112906.

170. Lyu XY, Deng Y, Huang XY, Li ZZ, Fang GQ, Yang D, et al. CRISPR FISHer enables high-sensitivity imaging of nonrepetitive DNA in living cells through phase separation-mediated signal amplification. *Cell Res*. 2022;32(11):969-981.

171. Bravo J, Hallmark T, Naegle B, Beisel CL, Jackson RN, Taylor DW. RNA targeting unleashes indiscriminate nuclease activity of CRISPR-Cas12a2. *Nature*. 2023.

172. Dmytrenko O, Neumann GC, Hallmark T, Keiser DJ, Crowley VM, Vialletto E, et al. Cas12a2 elicits abortive infection through RNA-triggered destruction of dsDNA. *Nature*. 2023:1-7.